Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Drug Prior Auth Policy | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy N/A

    Pharmacy and Specialty Drug Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all zing_health policy alerts

    Know when zing_health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs Zing Health prior authorization requirements for a broad set of prescription, specialty, infused, and biologic drugs. It specifies covered indications, clinical documentation, prerequisite or step therapy, prescriber requirements, coverage duration, and Medicare Part B versus Part D handling.

    Policy Summary
    PayerZing Health
    PolicyPharmacy and Specialty Drug Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with the applicable clinical criteria and supporting documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Plan yearStandard coverage duration
    3 monthsAbrysvo and Arexvy coverage duration
    Part A/BPart D denial condition
    65+High-risk medication age threshold
    40+

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Drug groups represented

    Drug-Specific Coverage Criteria

    Drug-Specific Coverage Requirements

    Covered when the applicable drug-specific indication, diagnostic, biomarker, prerequisite, age, route, prescriber, safety, and duration requirements below are met. Coverage is limited to FDA-approved or medically accepted indications unless an explicitly listed off-label indication is documented.

    Drug-specific requirements

    • ALK-positive malignancies: for ALK-directed therapy, document recurrent, advanced, metastatic, or otherwise qualifying disease and confirmation of ALK positivity or ALK fusion/translocation, as applicable.
    • Alosetron: for severe diarrhea-predominant IBS, patient is biologically female or identifies as female, symptoms have lasted at least 6 months, gastrointestinal abnormalities have been ruled out, and response to one conventional therapy was inadequate.
    • Brivaracetam and Bysanti: document the covered seizure or psychiatric indication and inadequate response, intolerance, or contraindication to the required generic and/or brand prerequisite therapies.
    • Cabometyx oncology criteria: document the qualifying advanced, relapsed, metastatic, recurrent, unresectable, or subsequent-treatment disease; required RET, VEGFR, or other biomarker; and prior therapies when required, including at least two FDA-approved therapies for eligible GIST.
    • Plaque psoriasis topical therapy: for calcipotriene or calcipotriene-betamethasone, document inadequate response or intolerance to at least one topical corticosteroid, or a contraindication to topical corticosteroids.
    • Calquence lymphoma criteria: for marginal zone lymphoma, document relapsed, refractory, or progressive disease; for other qualifying lymphoma indications, document the applicable FDA-approved diagnosis.
    • Cavhanza CML criteria: confirm Philadelphia chromosome or BCR-ABL; after resistance to another TKI, document absence of T315I, Y253H, E255K/V, and F359V/C/I mutations; and document prior nilotinib trial/intolerance, difficulty swallowing solid dosage forms, or concurrent PPI/H2RA use.
    • CeQur initial therapy: patient requires insulin management, monitors or will be counseled to monitor glucose or uses CGM, and has failed or cannot use bolus injections because of glycemic failure or difficulty administering multiple daily injections.
    • Rare-disease diagnostic criteria: for enzyme, storage, metabolic, and genetic disorders, diagnosis must be confirmed by the specified enzyme assay, biochemical testing, genetic testing, or other disease-specific diagnostic test; document symptomatic disease where required.
    • Clomipramine criteria: document failed, intolerant, or contraindicated SSRI/SNRI or other required antidepressant therapy; for anxiety, document concurrent bridging therapy or failure/intolerance/contraindication to at least two SSRIs/SNRIs; for patients 65 or older, document medical necessity when combining anticholinergic or CNS-active drugs.
    • Targeted oncology criteria: document disease stage, recurrence or progression, required molecular alteration, prior therapy, combination regimen, and line of therapy specified for the requested agent.
    • Cresemba criteria: use must be oral; for invasive aspergillosis or HIV-associated fluconazole-refractory esophageal candidiasis, document inadequate response, intolerance, or contraindication to voriconazole.
    • Dalfampridine multiple sclerosis criteria: initial therapy requires sustained walking impairment; continuation requires improved walking speed or another objective walking measure.
    • Hematologic oncology criteria: document the qualifying leukemia, lymphoma, myeloma, myelodysplastic, myeloproliferative, mast-cell, or eosinophilic neoplasm, required mutation or fusion, disease phase, prior therapy, and response or resistance status.
    • Deferasirox criteria: for transfusional iron overload, pretreatment serum ferritin must exceed 1000 mcg/L.
    • Drizalma Sprinkle criteria: for MDD, document failure, intolerance, or contraindication to two specified antidepressants; for GAD, diabetic neuropathy, fibromyalgia, chronic musculoskeletal pain, or chemotherapy neuropathic pain, document duloxetine capsule trial or inability to use capsules.
    • Droxidopa initial and continuation therapy: initial therapy requires persistent orthostatic blood-pressure reduction of at least 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing or tilt testing; continuation requires sustained symptom reduction; the nOH must be associated with an accepted neurologic or autonomic diagnosis.
    • Eligard criteria: for androgen-receptor-positive salivary gland tumors, disease must be recurrent, metastatic, or unresectable.
    • Ensacove and ENSACOVE: for ALK-positive NSCLC, document recurrent, advanced, or metastatic disease and either no prior ALK inhibitor or intolerance/progression on crizotinib.
    • Dasatinib/nOH initial and continuation therapy: for CML or ALL, document the required Philadelphia chromosome/BCR-ABL or ABL-class alteration and mutation restrictions; for nOH, apply the initial and continuation requirements stated for droxidopa.
    • Erivedge, Erleada, and Erlotinib: document prior systemic therapy and sonic-hedgehog alteration for adult medulloblastoma; GnRH analog or bilateral orchiectomy for Erleada; and EGFR-mutated recurrent, advanced, or metastatic NSCLC or qualifying pancreatic cancer for erlotinib.
    • Everolimus: document HR-positive/HER2-negative advanced breast cancer with required combination and subsequent therapy, advanced or stage IV RCC, adjuvant SEGA, qualifying progressed GIST, or required PIK3CA mutation for ECD, Rosai-Dorfman disease, or LCH.
    • Fabrazyme and Fanapt: confirm Fabry disease by enzyme assay or genetic testing, or symptomatic obligate carrier status; for Fanapt, document required prior generic and brand antipsychotic trials for schizophrenia or bipolar mania.
    • Fentanyl patch and Fetzima: fentanyl requires cancer, sickle-cell, terminal, palliative, or severe persistent opioid-requiring pain plus safe opioid exposure, monitoring for opioid use disorder, and required prior opioid duration; Fetzima requires failure, intolerance, or contraindication to two specified antidepressants.
    • Filspari and Flucytosine: for IgAN, confirm kidney biopsy and inadequate response, intolerance, or contraindication to maximally tolerated RAS inhibition; flucytosine must be used orally, with indication-specific duration.
    • Fotivda and Fruzaqla: document advanced, relapsed, refractory, or stage IV RCC after at least two systemic therapies; or advanced/metastatic colorectal or appendiceal cancer treated as single-agent second-line or later therapy.
    • Gattex and Haegarda: Gattex initial SBS therapy requires parenteral-support dependence and continuation requires reduced parenteral-support need; Haegarda requires laboratory-confirmed HAE with C1-inhibitor deficiency/dysfunction or qualifying normal-C1-inhibitor HAE evidence.
    • Gavreto, Gefitinib, and Gilotrif: document recurrent, advanced, or metastatic RET-positive NSCLC for Gavreto; sensitizing EGFR-mutated recurrent, advanced, or metastatic NSCLC for gefitinib; and EGFR-positive disease with required prior-agent intolerance/contraindication or platinum progression for Gilotrif.
    • HER2-directed therapy and HER2 oncology indication criteria: document HER2 positivity or amplification, RAS/BRAF status where applicable, qualifying disease stage, and the required combination with pertuzumab, tucatinib, lapatinib, or chemotherapy; Part D coverage is denied when Part A or Part B applies.
    • Tricyclic antidepressant criteria: for depression, document trials and inadequate response or intolerance to two specified alternatives; for anxiety, document trials and failure/intolerance to two specified alternatives or acute anxiety; for older adults, document benefit-risk assessment and medical necessity for concurrent anticholinergic or CNS-active therapy.
    • High-risk medication safety criteria: for patients 65 or older, the prescriber must attest that benefits outweigh risks and that concurrent anticholinergic or CNS-active medications are medically necessary; applicable cumulative-day limits must be observed.
    • Benztropine criteria: for EPS, document contraindication to or failure/intolerance of amantadine; for Parkinson's disease, document failure/intolerance of two of amantadine, carbidopa/levodopa, pramipexole, or ropinirole.
    • Anxiety criteria: document acute anxiety or failure, intolerance, or contraindication to at least two of buspirone, duloxetine, escitalopram, sertraline, or venlafaxine ER, with required age-related safety attestation.
    • Zolpidem criteria: for insomnia in patients 65 or older, document contraindication to or failure/intolerance of doxepin 3 or 6 mg or ramelteon, benefit-risk acknowledgment, and medical necessity for multiple CNS-active drugs; authorization applies beyond 90 cumulative days per year.
    • Promethazine criteria: for rhinitis, document failure/intolerance to two specified non-HRM alternatives; for all indications in older adults, document benefit-risk assessment and necessity of concurrent anticholinergics, with the applicable 30-day annual threshold.
    • Hydroxyzine alcohol withdrawal criteria: document benefit-risk acknowledgment and failure, intolerance, or contraindication to clorazepate or lorazepam; anxiety criteria and older-adult safeguards also apply.
    • Icatibant hereditary angioedema criteria: acute HAE attack must be documented with laboratory-confirmed C1-inhibitor deficiency/dysfunction or qualifying normal-C1-inhibitor HAE evidence; prescribing is by or in consultation with an immunologist, allergist, or rheumatologist.
    • Iclusig hematologic and GIST criteria: document qualifying accelerated/blast or resistant CML, T315I or mutation-negative status as applicable, Philadelphia chromosome/BCR-ABL for ALL, and GIST progression after at least two FDA-approved therapies.
    • Idhifa AML and MDS: AML must have an IDH2 mutation and be newly diagnosed and unsuitable for intensive induction, post-induction, relapsed/refractory, or consolidation; MDS must have an IDH2 mutation.
    • Imatinib oncology criteria: document Philadelphia chromosome/BCR-ABL for CML or Ph+ ALL and required TKI history; for melanoma, document unresectable/metastatic c-KIT-mutated disease and progression, intolerance, or risk with BRAF-targeted therapy; qualifying lymphoma and neoplasm criteria also apply.
    • Imkeldi: document inability to use imatinib tablets plus the applicable CML/ALL, melanoma, cGVHD, chordoma, Kaposi sarcoma, or eosinophilic-neoplasm criteria.
    • Increlex growth failure: before therapy, document height and basal IGF-1 at least 3 SD below age/sex mean and normal or elevated GH stimulation; continuation requires improvement.
    • Inluriyo breast cancer: recurrent, advanced, or metastatic HR-positive/HER2-negative, ESR1-mutated disease that progressed after at least one endocrine therapy.
    • Hydrocodone extended-release and morphine extended-release: require cancer, sickle-cell, terminal, palliative, or severe persistent pain, safe opioid dosing, monitoring for opioid use disorder, and at least 30 days of extended-release or one week of immediate-release opioid exposure for continuation.
    • Ivermectin exclusion: coverage is excluded for prevention or treatment of COVID-19.
    • Kalydeco cystic fibrosis: document CF and do not use with another CFTR potentiator; prescribing is by or in consultation with an appropriate CF specialist.
    • Kanjinti oncology criteria: document qualifying HER2-positive disease, required combination and RAS/BRAF status, and intolerance to Trazimera not attributable to the active ingredient; Part A/B precedence applies.
    • Ketoconazole criteria: exclude acute or chronic liver disease and contraindicated interacting drugs; document benefit-risk assessment and qualifying systemic fungal infection or Cushing syndrome when applicable.
    • General drug-specific authorization framework: requests must identify drug, indication, diagnosis, required laboratory or molecular confirmation, prior and prerequisite therapy, age, route, prescriber specialty, safety exclusions, continuation response, and requested duration.
    • Central precocious puberty: confirm pubertal GnRH response or pubertal third-generation LH, supportive bone-age assessment, and secondary-sex-characteristic onset before age 8 in females or 9 in males; age limits are less than 12 for females and less than 13 for males.
    • Mavyret hepatitis C: confirm HCV RNA and document genotype, prior treatment, cirrhosis status, HIV, resistance substitutions, and transplant status; exclude decompensated cirrhosis and follow current AASLD-IDSA guidance.
    • Nuedexta initial and continuation therapy and Nuedexta pseudobulbar affect: initial therapy requires neurologic disease or injury causing involuntary, sudden, frequent laughing or crying; continuation requires fewer PBA episodes.
    • Lynparza breast cancer: document recurrent/metastatic or preoperative-unresponsive BRCA- or PALB2-mutated disease, or high-risk early HER2-negative BRCA-mutated disease requiring adjuvant therapy; ovarian maintenance, prostate, and uterine leiomyosarcoma criteria also apply.
    • Ogivri and Ontruzant disease-specific criteria: apply the HER2-directed therapy requirements, including qualifying colorectal, hepatobiliary, endometrial, appendiceal, and other HER2-positive cancers, required combinations, Trazimera intolerance, and Part A/B precedence.
    • Omnipod initial therapy: patient requires insulin with multiple daily injections, self-tests glucose at least four times daily or uses CGM, and for non-type 1 diabetes has inadequate control, recurrent hypoglycemia, wide fluctuations, dawn phenomenon, or severe excursions.
    • Opipza indication-specific criteria: document failure, intolerance, contraindication, or inability to swallow oral formulations for schizophrenia, adjunctive MDD, autistic irritability, Tourette's disorder, or schizoaffective disorder, using the specified generic and brand alternatives.
    • Orserdu coverage: recurrent, advanced, or metastatic or preoperative-unresponsive ER-positive/HER2-negative ESR1-mutated breast cancer used as subsequent therapy.
    • Pazopanib indication criteria: document advanced/relapsed/stage IV RCC or VHL-associated RCC; for GIST, document qualifying residual, unresectable, recurrent/metastatic or ruptured disease and progression after at least two approved therapies or SDH deficiency.
    • Perampanel seizure criteria: for focal seizures, document failure/intolerance/contraindication to a generic anticonvulsant and Xcopri when age 18 or older; for generalized tonic-clonic seizures, document failure/intolerance/contraindication to a generic anticonvulsant.
    • Pimecrolimus medical necessity: for mild-to-moderate atopic dermatitis, document sensitive-site disease or failure/intolerance/contraindication to a first-line topical corticosteroid; use must be short-term or non-continuous chronic therapy.
    • Sodium phenylbutyrate: chronic UCD management requires enzymatic, biochemical, or genetic confirmation of a urea cycle disorder.
    • Sapropterin initial and continuation: for PKU, initial pretreatment phenylalanine must exceed 6 mg/dL (360 micromol/L); continuation requires documented improvement, such as reduced phenylalanine or improved neuropsychiatric symptoms.
    • Lanreotide acromegaly: initial therapy requires elevated pretreatment IGF-1 and inadequate or partial response to, or inability to undergo, surgery or radiotherapy; continuation requires decreased or normalized IGF-1.
    • Synarel central precocious puberty: apply the specified GnRH/LH, bone-age, onset-age, and sex-specific age requirements; endometriosis treatment is limited to a maximum of 6 months.
    • Tavneos ANCA-associated vasculitis: confirm GPA or MPA by MPO- or PR3-antibody serology and use as adjunctive therapy with standard treatment; continuation requires benefit.
    • Tasimelteon Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome: Non-24 requires total blindness and inability to perceive light, with sleep benefit for continuation; SMS requires confirmed diagnosis and improved sleep quality for continuation, with age and specialist requirements.
    • Temazepam short-term insomnia: in patients 65 or older, document benefit-risk acknowledgment, failure/intolerance/contraindication to doxepin or ramelteon, and medical necessity for multiple CNS-active drugs.
    • Testosterone cypionate hypogonadism and gender dysphoria: initial hypogonadism requires two low morning testosterone levels; continuation requires a low level before therapy; gender dysphoria requires informed decision-making.
    • Terbinafine onychomycosis: oral therapy must be for dermatophyte onychomycosis and non-continuous use; authorization applies beyond 90 cumulative days per year and is limited to 12 weeks.
    • Testosterone initial, continuation, and gender dysphoria: apply the same two-confirmed-low-level initial criterion, pretherapy confirmation for continuation, and informed-decision criterion for gender dysphoria across injectable, topical, and other covered formulations.
    • Tibsovo mutation and disease criteria: disease must have a susceptible IDH1 mutation; AML, cholangiocarcinoma, and CNS cancer require the specified disease phase, prior-treatment, recurrence/progression, or adjuvant criteria.
    • Treprostinil pulmonary arterial hypertension: confirm WHO Group 1 PAH by right-heart catheterization; new starts require mean pulmonary artery pressure greater than 20 mmHg, wedge pressure 15 mmHg or less, and pulmonary vascular resistance greater than 2 Wood units.
    • TruQap breast cancer: recurrent, locally advanced, or metastatic HR-positive/HER2-negative disease with PIK3CA, AKT, or PTEN alteration, used with fulvestrant after endocrine progression or recurrence within 12 months of adjuvant therapy.
    • Tukysa oncology criteria: document HER2-positive recurrent/advanced/unresectable/metastatic breast cancer or qualifying HER2-positive RAS-wild-type colorectal, appendiceal, or biliary disease, with required trastuzumab combination and prior-therapy conditions.
    • Prerequisite and prior therapy: when a request requires prerequisite therapy, document an inadequate response, intolerance, contraindication, or other expressly stated reason the prerequisite cannot be used; document the required line and number of prior therapies.
    • Disease and biomarker confirmation: when criteria specify a mutation, fusion, amplification, receptor, chromosome, gene, enzyme deficiency, or biopsy, submit the corresponding pathology, laboratory, genetic, molecular, or imaging report.
    • Zejula uterine leiomyosarcoma: at least one prior therapy and BRCA-altered disease; ovarian, fallopian-tube, or primary-peritoneal maintenance requires stage II-IV or recurrent disease in complete or partial chemotherapy response.
    • Zejula prostate cancer: BRCA-mutated disease treated with abiraterone and an oral corticosteroid, together with GnRH analog therapy or prior bilateral orchiectomy.
    • Zejula gynecologic cancer maintenance: ovarian, fallopian-tube, or primary-peritoneal cancer must be stage II-IV or recurrent and in complete or partial response to chemotherapy.
    • Zelboraf CNS cancer: BRAF V600E-positive glioma or glioblastoma requires cobimetinib combination, while pediatric diffuse high-grade glioma may qualify under the stated indication.
    • Zelboraf melanoma: BRAF V600 activating mutation-positive unresectable, limited-resectable, or metastatic disease, or qualifying adjuvant/neoadjuvant therapy, as monotherapy or with cobimetinib.
    • Zelboraf Erdheim-Chester disease and Langerhans cell histiocytosis: tumor must be BRAF V600 mutation-positive.
    • Zelboraf non-small cell lung cancer: BRAF V600E-positive recurrent, advanced, or metastatic disease.
    • Zonisade seizure therapy: for focal seizures, document difficulty swallowing solid dosage forms or failure/intolerance/contraindication to a generic anticonvulsant and Xcopri when age 18 or older; minimum age is 16 years.
    • Zurzuvae postpartum depression: diagnosis must be confirmed with a standardized depressive-symptom rating scale such as HDRS, EPDS, PHQ-9, MADRS, or BDI; coverage is limited to one month.
    • Zyprexa Relprevv tolerability: tolerability with oral olanzapine must be established before depot therapy.

    Coverage is excluded when the requested use is not a covered FDA-approved or medically accepted indication, when required diagnostic or biomarker confirmation is absent, when required prerequisite or prior therapy has not been completed without a documented exception, or when the request conflicts with an explicitly stated contraindication, interaction, route, age, duration, or specialist requirement.

    Coverage under Part D will be denied when the medication is prescribed, dispensed, or administered for an individual in a circumstance where Medicare Part A or Part B coverage applies. Requests may also be denied for prohibited combinations, including potent CYP3A4 inhibitors where specified, contraindicated ketoconazole interactions, concurrent CFTR potentiators, or other product-specific exclusions.

    Authorization durations are indication-specific. Where no special duration is stated, the authorization period is the plan year; initial and continuation durations, short-term limits, cumulative annual day limits, and specialist requirements stated in the applicable criteria must be followed.

    Initial Therapy Criteria

    Initial or new-start authorization requires documentation of the applicable entry criteria before therapy begins.

    Initial therapy

    • The patient has the covered diagnosis and the disease is at the required stage, severity, recurrence, progression, or risk level.
    • Required disease, biomarker, mutation, fusion, receptor, enzyme, chromosome, biopsy, laboratory, imaging, or genetic confirmation is documented.
    • The requested drug is being used for the covered indication, route, formulation, combination regimen, and line of therapy.
    • All required prerequisite and prior therapies have been tried, were ineffective, not tolerated, or are contraindicated, unless the drug-specific criterion provides another qualifying pathway.
    • Age, specialist-prescriber, safety, interaction, Medicare Part A/B, and other product-specific restrictions are satisfied.

    Continuation Therapy Criteria

    Continuation authorization requires evidence that therapy remains clinically appropriate and that the patient is benefiting without unacceptable toxicity.

    Continuation therapy

    • The patient remains diagnosed with the covered condition and continues to meet the applicable disease, biomarker, and indication requirements.
    • The patient has achieved, maintained, or demonstrated a clinically meaningful benefit, response, improvement, reduced symptoms, improved laboratory or imaging findings, or other drug-specific continuation outcome.
    • The patient is tolerating therapy without unacceptable toxicity, and required laboratory, safety, monitoring, and specialist oversight are documented.
    • Required concurrent therapy, such as GnRH analog therapy, urate-lowering therapy, standard vasculitis therapy, endocrine therapy, or combination oncology therapy, is continuing when specified.

    Prerequisite and Step-Therapy Requirements

    Drug(s) / indicationStepRequired prior therapy or sequenceFailure standard or exception
    Arcalyst — gout-flare prevention1Use maximum tolerated NSAID and colchicine, with concurrent urate-lowering therapy.Inadequate response, intolerance, or contraindication to both NSAID and colchicine; at least two gout flares in the prior 12 months also required for new starts.
    Atovaquone — PCP treatment or primary toxoplasmosis prophylaxis1Sulfamethoxazole/trimethoprim (SMX-TMP).Inadequate response, intolerance, or contraindication; prophylaxis also requires immunocompromised status.
    Atovaquone — babesiosis1Azithromycin concurrently.Concurrent therapy is required; no failure exception stated.
    Bosulif / bosutinib — CML1Imatinib, dasatinib, or nilotinib.Resistance or intolerance; resistant cases must also be negative for specified mutations.
    Brivaracetam — focal-onset seizures1A generic anticonvulsant; Xcopri when the patient is 18 or older.Inadequate response, intolerance, or contraindication to the applicable therapy.
    Bysanti — schizophrenia or bipolar I mania/mixed episodes1One listed generic antipsychotic followed by one listed brand antipsychotic.Inadequate response, intolerance, or contraindication to each step.
    Cabometyx — GIST1At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib.Disease progression after the prior therapies.
    Antipsychotics — schizophrenia1 → 2One listed generic antipsychotic, followed by one listed brand antipsychotic.Inadequate response, intolerance, or contraindication at each step.
    Antipsychotics — acute bipolar I mania or mixed episode1 → 2One listed generic antipsychotic, followed by Lybalvi or Vraylar.Inadequate response, intolerance, or contraindication at each step.
    Calcipotriene or Enstilar — plaque psoriasis1At least one topical corticosteroid.Inadequate response or intolerance, unless a contraindication prevents a corticosteroid trial.
    Cresemba — invasive aspergillosis or fluconazole-refractory HIV-associated esophageal candidiasis1Voriconazole before Cresemba.Inadequate response, intolerance, or contraindication to voriconazole.
    Drizalma Sprinkle — major depressive disorder1Two antidepressant agents or classes selected from SNRIs, SSRIs, mirtazapine, or bupropion.Inadequate response, intolerance, or contraindication to two alternatives.
    Ensacove — ALK-positive NSCLC1Prior ALK-inhibitor therapy when previously treated.No prior ALK inhibitor is acceptable; otherwise intolerance or progression with crizotinib is required.
    Droxidopa / nOH1Qualifying nOH diagnosis and objective orthostatic blood-pressure decrease before initial therapy.Systolic decrease of at least 20 mmHg or diastolic decrease of at least 10 mmHg within 3 minutes; continuation requires sustained symptom reduction.
    Ergotamine — migraine1At least one triptan 5-HT1 agonist.Inadequate response, intolerance, or contraindication.
    Eprontia — focal-onset seizures1A generic anticonvulsant; Xcopri when the patient is 18 or older.Inadequate response, intolerance, or contraindication to the applicable therapy.
    Fanapt — schizophrenia or bipolar I mania/mixed episodes1 → 2One listed generic antipsychotic followed by one listed brand antipsychotic.Inadequate response, intolerance, or contraindication to each step.
    EMSAM, Exxua, or Fetzima — major depressive disorder1Two agents or classes selected from SNRIs, SSRIs, mirtazapine, or bupropion.Failure, intolerance, or contraindication; EMSAM also permits inability to swallow oral formulations.
    Gilotrif — EGFR-positive NSCLC1Erlotinib, gefitinib, or osimertinib.Intolerable adverse event or contraindication; metastatic squamous NSCLC instead requires prior platinum-based chemotherapy.
    Tricyclic antidepressants — depression1Two alternatives from SSRIs, SNRIs, bupropion, mirtazapine, or trazodone.Inadequate response or intolerance to two alternatives.
    Benztropine — extrapyramidal symptoms1Amantadine.Inadequate response or intolerance after a trial, or contraindication without a prior trial.
    Benztropine — Parkinson’s disease1Two of amantadine, carbidopa/levodopa, pramipexole, or ropinirole.Inadequate response or intolerance to two alternatives.
    High-risk medications — anxiety1Two of buspirone, duloxetine, escitalopram, sertraline, or venlafaxine extended-release.Inadequate response or intolerance to two alternatives; acute anxiety is an exception.
    Zolpidem — insomnia1Doxepin 3 mg or 6 mg, or ramelteon.Trial with inadequate response or intolerance, or contraindication to both alternatives.
    Promethazine — rhinitis1Two of levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal.Inadequate response or intolerance to both alternatives.
    Hydroxyzine — alcohol withdrawal syndrome1Clorazepate or lorazepam.Inadequate response or intolerance after a trial, or contraindication without a prior trial.
    Zolpidem — depression1Two SSRIs, SNRIs, bupropion, mirtazapine, or trazodone alternatives.Inadequate response or intolerance to two alternatives.
    Iclusig — chronic-phase CML1At least two prior kinase inhibitors, including imatinib, dasatinib, or nilotinib when applicable.Resistance or intolerance; exceptions include accelerated/blast phase, T315I mutation, or specified BCR-ABL1 resistance pathway.
    Iclusig — GIST1At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib.Disease progression after prior therapy.
    Imatinib or Imkeldi — c-KIT-mutated cutaneous melanoma1Prior BRAF-targeted therapy.Progression, intolerance, or risk of progression with BRAF-targeted therapy.
    Imatinib — selected lymphoma indications1Subsequent, second-line, or later therapy, or prior chemoimmunotherapy as applicable.Relapsed/refractory disease or the specified prior-treatment setting.
    Inluriyo — recurrent breast cancer1At least one line of endocrine therapy.Disease progression following endocrine therapy.
    Extended-release hydrocodone or morphine1Alternative pain therapy, including immediate-release opioids; continuation requires at least 30 days of extended-release opioid therapy or 1 week of immediate-release opioid therapy.Alternatives inadequate; qualifying opioid exposure and safe dosing must be documented.
    Jakafi — specified polycythemia vera or essential thrombocythemia indications1Hydroxyurea, Besremi, interferon therapy, or anagrelide, as applicable.Inadequate response, intolerance, resistance, or loss of response as specified.
    Leqembi Iqlik — maintenance therapy1At least 18 months of prior intravenous lecanemab-irmb infusions.Minimum prior-treatment duration is required.
    Megestrol acetate — cancer-related cachexia1Megestrol 40 mg/mL oral suspension.Inadequate response or intolerance.
    Lorbrena — ROS1-positive NSCLC1Crizotinib, entrectinib, repotrectinib, or taletrectinib.Disease progression on the prior ROS1-directed therapy.
    Mekinist or Mektovi — BRAF-mutated indications1Required BRAF-directed combination: dabrafenib or encorafenib, depending on indication.Combination therapy is required; no general failure exception stated.
    Mavyret — hepatitis C1Treatment conditions and regimen selection must follow current AASLD-IDSA guidance.Requirements vary by genotype, prior treatment, cirrhosis, resistance, HIV, and transplant status.
    Lynparza — breast cancer pathway 11At least two prior therapies.Required for recurrent, advanced, metastatic, or preoperative-treatment-unresponsive disease; an early-stage HER2-positive pathway follows adjuvant trastuzumab-based therapy instead.
    Opipza — indication-specific psychiatric use1 → 2Specified generic and, where applicable, brand antipsychotic trials.Failure, intolerance, or contraindication; inability to swallow oral formulations is an alternative pathway.
    Pazopanib — GIST1At least two FDA-approved treatments, such as imatinib, sunitinib, regorafenib, or ripretinib.Disease progression; step is not required when GIST is SDH-deficient.
    Perampanel — partial-onset seizures1 → 2A generic anticonvulsant, followed by Xcopri for adults.Inadequate response, intolerance, or contraindication to each applicable therapy.
    Pimecrolimus — atopic dermatitis1At least one first-line topical therapy, such as a medium- or higher-potency topical corticosteroid, when sensitive-area criteria are not met.Inadequate response, intolerance, or contraindication.
    Perampanel — seizure indications1 → 2Generic anticonvulsant; Xcopri additionally for adults with partial-onset seizures.Inadequate response, intolerance, or contraindication to the required therapy.
    Pimecrolimus — first-line therapy pathway1At least one first-line therapy, such as a medium- or higher-potency topical corticosteroid.Required when qualifying sensitive-area disease is not established; failure, intolerance, or contraindication applies.
    Quetiapine extended-release1Specified generic antipsychotic alternatives according to indication.Inadequate response, intolerance, or contraindication.
    Remicade or Renflexis — new starts1Methotrexate, NSAID, immunosuppressive therapy, phototherapy, or specified conventional agents, as applicable to the indication.Inadequate response, intolerance, or contraindication; severity-based psoriasis pathways may apply.
    Qinlock — GIST1 → 2 → 3At least three kinase inhibitors including imatinib, or imatinib followed by second-line sunitinib.Intolerance to second-line sunitinib is an alternative to completing three inhibitors.
    Rubraca — metastatic castration-resistant prostate cancer1Androgen receptor-directed therapy, with concurrent GnRH analog therapy or bilateral orchiectomy.Prior androgen receptor-directed therapy is required.
    Scemblix — chronic-phase CML1Imatinib, dasatinib, or nilotinib, unless the T315I pathway applies.Resistance or intolerance, or qualifying prior treatment for previously treated CML.
    Sorafenib — GIST1At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib.Disease progression after prior therapy.
    Stivarga — colorectal cancer1Prior treatment and Lonsurf (trifluridine/tipiracil) when applicable.Inadequate response, intolerance, or contraindication to Lonsurf.
    Tadalafil — BPH1 → 2Both an alpha blocker and a 5-alpha reductase inhibitor.Inadequate response, intolerance, or contraindication to both.
    Tasigna / nilotinib — GIST1At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib.Disease progression after prior therapy.
    Temazepam — short-term insomnia1Doxepin 3 mg or 6 mg, or ramelteon.Inadequate response, intolerance, or contraindication; applies to patients 65 years or older.
    Tofacitinib — applicable inflammatory conditions1At least one TNF inhibitor.Inadequate response, intolerance, or contraindication for new starts; continuation requires beneficial response.
    Trintellix — major depressive disorder1At least one generic SNRI, SSRI, mirtazapine, or bupropion.Inadequate response, intolerance, or contraindication.
    Truxima — rheumatoid arthritis1Methotrexate or a prior biologic or targeted synthetic DMARD.Inadequate response, intolerance, or contraindication to methotrexate, or inadequate response/intolerance to prior DMARD therapy.
    Ubrelvy — acute migraine1At least one triptan 5-HT1 receptor agonist.Inadequate response, intolerance, or contraindication.
    Uceris — active mild-to-moderate ulcerative colitis1At least one 5-ASA therapy.Inadequate response, intolerance, or contraindication.
    Ubrelvy — acute migraine1At least one triptan 5-HT1 receptor agonist.Inadequate response, intolerance, or contraindication.
    Uceris — active mild-to-moderate ulcerative colitis1At least one 5-ASA therapy.Inadequate response, intolerance, or contraindication.
    Versacloz — treatment-resistant schizophrenia1 → 2One listed generic antipsychotic followed by one listed brand antipsychotic.Inadequate response, intolerance, or contraindication to each step.
    Xyrem — adult narcolepsy with excessive daytime sleepiness1A CNS wakefulness-promoting drug, such as armodafinil or modafinil.Inadequate response, intolerance, or contraindication; not required for patients younger than 18 or for cataplexy-only requests.
    Wyost or Xtrenbo — hypercalcemia of malignancy1Intravenous bisphosphonate therapy.Disease must be refractory, or there must be a clinical reason to avoid IV bisphosphonate therapy.
    Zonisade — partial-onset seizures1 → 2A generic anticonvulsant and, for patients 18 or older, Xcopri.Inadequate response, intolerance, or contraindication; difficulty swallowing solid oral dosage forms is an alternative pathway.

    Prior Authorization and Submission Requirements

    Prior Authorization

    Drug-Specific PA and Prerequisite Requirements

    Obtain drug-specific prior authorization and submit the indication, diagnosis, treatment setting, prior therapies, objective findings, age, duration, and prescriber information required for the requested product. Coverage is limited to the listed FDA-approved or medically accepted indications and prerequisites; document failure, intolerance, contraindication, or inability to use each required alternative.

    • General PA: Confirm the requested drug, indication, formulation, dose, route, treatment line, and whether the request is initial or continuation therapy. Submit indication-specific clinical documentation rather than relying on a generic PA.
    • Specialists: Arikayce requires a pulmonologist, infectious-disease specialist, or prescriber experienced in Mycobacterium avium complex lung disease. Berinert and icatibant require an immunologist, allergist, or rheumatologist (or consultation with one). Fabrazyme, Lumizyme, and rare metabolic therapies require metabolic-disease or lysosomal-storage-disorder expertise; Gattex requires gastroenterology, gastrointestinal-surgery, or nutritional-support expertise.
    • Antipsychotic and antidepressant steps: Document sequential trials, inadequate response, intolerance, or contraindication to required generic and brand alternatives for Fanapt, Opipza, Versacloz, clomipramine, Emsam, Exxua, Fetzima, Trintellix, and related products. Treatment-resistant schizophrenia requires failure, intolerance, or contraindication to a listed generic and a listed brand antipsychotic.
    • Topical and dermatologic steps: Calcipotriene and calcipotriene-betamethasone require a topical corticosteroid trial or contraindication. Pimecrolimus requires sensitive-area disease or failure/intolerance/contraindication to first-line topical corticosteroid therapy and must be short-term or non-continuous. Topical lidocaine requires topical-anesthesia use and FDA-approved topical ingredients in compounded products.

    Clinical Thresholds and Operational Values

    Clinical thresholds and measurements
    Laboratory thresholdsAlpha1-proteinase inhibitor: less than 11 micromol/L, equivalent to less than 80 mg/dL by radial immunodiffusion or less than 50 mg/dL by nephelometry; Ayvakit platelet count: at least 50,000/microliter; deferasirox ferritin: greater than 1000 mcg/L.
    Age thresholdsEprontia: at least 2 years for epilepsy, at least 12 years for migraine, and at least 18 years for the Xcopri sequencing requirement; Increlex: at least 2 years; icatibant: at least 18 years; Kalydeco: at least 1 month; Orkambi: at least 1 year; pimecrolimus: at least 2 years.
    Orthostatic blood-pressure responseFor initial neurogenic orthostatic hypotension therapy, systolic blood pressure must decrease by at least 20 mmHg or diastolic blood pressure by at least 10 mmHg within 3 minutes of standing or head-up tilt testing.
    Treatment-duration thresholdsClorazepate: more than 5 cumulative days of therapy per year; zolpidem: more than 90 cumulative days per year; terbinafine: more than 90 cumulative days per year triggers prior authorization.
    Body-surface-area thresholdsFor severe plaque psoriasis supporting biologic first-line therapy, at least 10% of body surface area must be affected; escalation criteria may apply at least 3% body surface area with inadequate response, intolerance, or contraindication to specified therapy.

    Definitions and Abbreviations

    Definitions and abbreviations
    GnRH analog or bilateral orchiectomyA gonadotropin-releasing hormone analog or surgical removal of both testes used as concurrent androgen-deprivation therapy.
    Platelet thresholdA platelet count greater than or equal to 50,000 per microliter, required for systemic mastocytosis treatment with Ayvakit.
    SLE and LNSLE means systemic lupus erythematosus; LN means lupus nephritis.
    RET-positive and BRAF V600 activating mutationRET-positive disease is disease with a rearrangement during transfection alteration. A BRAF V600 activating mutation includes variants such as V600E or V600K.
    Diagnostic confirmationDepending on the condition, diagnostic confirmation may be established by enzyme assay, genetic testing, or demonstration of corneal cystine crystals by slit-lamp examination.
    Neurogenic orthostatic hypotension

    Policy Scope and Context

    This document presents a drug-by-drug prior authorization table for prescription, specialty, infused, and medical-benefit products. It addresses oncology and targeted cancer therapies, biologics and immunologic treatments, vaccines, anti-infectives, neurologic and psychiatric medications, rare-disease and enzyme-replacement therapies, antifungals, diabetes-management products, opioid analgesics, and other specialty drugs. Requirements vary by product and may include an FDA-approved or medically accepted indication, disease stage, biomarker or genetic confirmation, prior treatment, treatment response, concurrent therapy, prescriber qualifications, coverage duration, and whether the request is payable under Medicare Part B or Part D. Most approvals are issued for the plan year, although selected vaccines, anti-infective therapies, and other products have shorter authorization periods.

    Policy Summary
    PayerZing Health
    PolicyPharmacy and Specialty Drug Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with the applicable clinical criteria and supporting documentation.
    SourceLink
    On This Page
    Drug-Specific Coverage CriteriaPrerequisite and Step-Therapy RequirementsPrior Authorization and Submission RequirementsClinical Thresholds and Operational ValuesDefinitions and AbbreviationsPolicy Scope and Context
    There is no new contraindication, prohibited interaction, Part A/B coverage issue, or failure to comply with applicable duration or quantity limits.
  1. Opioids and high-risk medications: Fentanyl patch and extended-release opioids require cancer, sickle-cell, terminal, palliative, or severe persistent pain documentation, opioid-tolerance history, safe dosing, monitoring for opioid-use disorder, and prior extended-release opioid use for at least 30 days or immediate-release opioid use for at least 1 week. Older adults require benefit-risk attestation and review of anticholinergic and CNS polypharmacy; document missing high-risk medication assessments.
  2. Tyrosine kinase and oncology prerequisites: Document molecular results, disease status, prior treatment, and required combinations for oncology therapies. Dasatinib requires disease-specific Philadelphia chromosome/BCR-ABL, mutation, prior-TKI, GIST, or melanoma criteria; avoid potent CYP3A4 inhibitors. Cabometyx requires disease-specific criteria and, for GIST, progression after at least two approved therapies. Targeted oncology requests must include tumor biomarker, line-of-therapy, and response/progression documentation.
  3. Selected A-H requirements: Abiraterone and Erleada require GnRH therapy or bilateral orchiectomy. Abrysvo and Mresvia require no prior RSV vaccine. Alpha1-proteinase inhibitor requires emphysema and serum level below 11 micromol/L. Atovaquone requires SMX-TMP intolerance/contraindication and, where applicable, immunocompromise or concurrent azithromycin. Benlysta requires diagnostic autoantibody or biopsy confirmation and continuation benefit. Berinert and icatibant require laboratory-confirmed hereditary angioedema or qualifying normal-C1-inhibitor genetic/family-history and antihistamine-refractory documentation. BRAF-targeted combinations require the specified BRAF mutation, disease status, and combination partner. Calcipotriene products require topical-corticosteroid step therapy; clomipramine requires SSRI/SNRI or depression-alternative failures and older-adult risk review. Clozapine/Fanapt/other antipsychotics require sequential generic and brand trials. Cresemba requires oral use and, for applicable indications, voriconazole failure/intolerance/contraindication. Cystinosis and Gaucher therapies require enzyme, genetic, or characteristic laboratory confirmation. Dexmethylphenidate requires ADHD/ADD or cancer-related fatigue after other causes are excluded. Emsam requires two antidepressant failures/intolerance/contraindication or inability to swallow oral therapy. Ensacove requires recurrent/advanced/metastatic ALK-positive NSCLC and no prior ALK inhibitor or crizotinib intolerance/progression. Eprontia requires anticonvulsant and, when applicable, Xcopri or generic-topiramate step therapy. Erivedge requires prior systemic therapy and sonic-hedgehog-pathway mutation; erlotinib requires EGFR-positive NSCLC or qualifying pancreatic disease. Everolimus requires indication-specific disease status, combination, and prior therapy. Exxua requires two antidepressant alternatives.
  4. Additional A-H requirements: Fabrazyme requires confirmed Fabry disease and specialist prescribing. Fentanyl requires opioid criteria; Fetzima requires two antidepressant alternatives. Filsp​​ari requires biopsy-confirmed IgA nephropathy and maximally tolerated RAS-inhibitor failure/intolerance/contraindication. Flucytosine requires oral use and indication-specific duration. Fotivda requires advanced/relapsed/refractory or stage IV RCC after at least two systemic therapies. Fruzaqla and Lonsurf require advanced/metastatic colorectal or appendiceal disease and subsequent-line use. Gattex requires short bowel syndrome with parenteral-support dependence initially and reduced support for continuation. Gefitinib, Gilotrif, and other EGFR therapies require EGFR-mutated NSCLC criteria; Gilotrif additionally requires erlotinib/gefitinib/osimertinib intolerance or contraindication, or platinum-treated squamous disease. Gomekli requires symptomatic, inoperable plexiform neurofibromas in NF1. Growth-failure therapy requires height, IGF-1, growth-hormone testing, age, and endocrinology documentation. Herceptin, Kanjinti, Ogivri, Ontruzant, Trazimera, and other trastuzumab products require oncology indication, biomarker, combination, and prior-treatment documentation.
  5. Documentation Required

    Clinical Evidence, Specialist, and Treatment-History Requirements

    For each request, submit objective clinical evidence and the required treatment history. Initial and continuation approvals are distinct: continuation generally requires documented benefit, response, improvement, reduced symptoms, or absence of toxicity.

    • I-K: Icatibant requires HAE eligibility, laboratory or genetic confirmation, age 18 or older, and specialist documentation; absence of established eligibility is a denial risk. Iclusig requires qualifying CML/ALL/GIST disease, prior kinase-inhibitor history, mutation results, and applicable resistance criteria. Imkeldi requires severe primary IGF-1 deficiency or GH-gene deletion with height, IGF-1, provocative GH testing, age, endocrinology, and continuation-improvement documentation. Inluriya requires recurrent/advanced/metastatic HR-positive, HER2-negative, ESR1-mutated breast cancer after endocrine therapy. Isturisa and Korlym require endocrinology involvement. Ivermectin is excluded for COVID-19 use. Kalydeco and Orkambi require CF eligibility, specialist involvement, and no duplicate or incompatible CFTR potentiator. Kanjinti and other biosimilars require the permitted substitution rule and Part A/Part B availability review. Oral ketoconazole requires medical necessity, qualifying fungal infection or Cushing syndrome, no hepatic disease, and no contraindicated interacting drugs. Kisqali requires the specified breast or endometrial indication and combination therapy. Koselugo requires qualifying recurrent/progressive tumor criteria. Krazati requires KRAS G12C-positive disease. Lazcluze requires EGFR exon 19 deletion or exon 21 L858R NSCLC. Lenalidomide requires the applicable hematologic indication and disease-risk documentation. Lenvima requires disease-specific status and, for endometrial cancer, progression after systemic therapy. Leqembi Iqlik requires at least 18 months of prior IV lecanemab infusions. Leukine requires timing at least 24 hours after chemotherapy and qualifying malignancy/prophylaxis criteria. Leuprolide, Lupron Depot-Ped, and Synarel require CPP diagnosis, bone-age assessment, age at onset, and sex-specific age limits. Lidocaine topical products require topical-anesthesia criteria and Part B/A versus Part D review; lidocaine patches require diabetic or cancer-related neuropathy. Livtencity requires age 12 or older, specialist prescribing, and transplant/CMV documentation. Lonsurf requires subsequent-line colorectal, gastric, esophageal, gastroesophageal-junction, or appendiceal disease. Lorbrena requires ALK-positive NSCLC or ROS1 disease with the required prior ROS1-directed therapy. Lumakras requires KRAS G12C-positive NSCLC with recurrent/advanced/metastatic disease; Lumizyme requires Pompe confirmation and specialty prescribing. Lynparza requires tumor-specific indication, mutation, prior therapy, and breast-cancer criteria; document required prior therapies. Mavyret requires HCV RNA, genotype, treatment history, cirrhosis and hepatic status, HIV, resistance, transplant status, and AASLD-IDSA guideline-based regimen. Megestrol requires prior megestrol suspension failure/intolerance. Mekinist requires BRAF mutation, disease status, and required combination. Memantine and methylphenidate require the applicable age, ADHD/ADD, narcolepsy, or cancer-fatigue criteria. Metyrosine requires alpha-adrenergic antagonist failure/intolerance/contraindication. Monjuvi requires relapsed, refractory, or progressive disease and subsequent-line use where specified. Mresvia requires no prior RSV vaccination. Naglazyme requires enzyme or genetic confirmation of MPS VI. Nerlynx requires specified HER2-positive breast-cancer status and prior therapy. Nitisinone requires biochemical, genetic, or enzyme confirmation of hereditary tyrosinemia type 1. Nubeqa requires GnRH therapy or bilateral orchiectomy.
    • Older-adult and CNS review: For high-risk medications, including zolpidem, temazepam, hydroxyzine, guanfacine, meclizine, promethazine, tricyclic antidepressants, cyclobenzaprine, and related products, document age 65 or older where applicable, benefit-risk attestation, duration limits, prerequisite alternatives, anticholinergic burden, CNS polypharmacy, and the medical necessity of concurrent CNS-active drugs. Zolpidem requires doxepin or ramelteon failure/intolerance/contraindication and has a cumulative 90-day annual limit; temazepam requires the same alternatives and short-term insomnia criteria.
    • Neurology, diabetes, and specialty products: Nuedexta requires neurologic disease or injury causing PBA initially and decreased episodes for continuation. Nuplazid requires Parkinson disease diagnosis before psychosis onset. Omnipod requires insulin use, multiple daily injections, glucose monitoring or CGM, and qualifying glycemic problems. Ojemda requires BRAF fusion/rearrangement or BRAF V600 testing. Opipza requires indication-specific generic/brand step therapy or inability to swallow oral formulations. Orkambi requires no incompatible CFTR combination and pulmonology/CF expertise. Orserdu requires ER-positive, HER2-negative, ESR1-mutated advanced disease and subsequent-line use. Pazopanib requires RCC or GIST disease and prior-treatment history. Perampanel requires generic anticonvulsant and, when applicable, Xcopri failure/intolerance/contraindication. Phenylbutyrate requires enzymatic, biochemical, or genetic confirmation of a urea-cycle disorder. Pimecrolimus requires restricted-use and medical-necessity documentation. Pirfenidone requires exclusion of other fibrosis causes, UIP or multidisciplinary diagnostic support, pulmonology expertise, and continuation benefit. Posaconazole requires oral use and weight/indication criteria. Prevymis requires transplant type, CMV serostatus, and prophylaxis documentation. Qinlock requires GIST or KIT-mutated melanoma criteria and the required kinase-inhibitor sequence. Quetiapine extended-release requires psychiatric indication and alternative-treatment documentation. Quinine requires babesiosis use with clindamycin. Raldesy requires inability to swallow trazodone tablets.
    Denial Risk

    Oncology, Continuation, and Denial-Risk Controls

    Document the exact disease, biomarker, prior treatment sequence, combination regimen, and response for oncology and specialty drugs. Requests lacking an established indication, required molecular result, prior treatment failure, or continuation response may be denied.

    • R-Z oncology and hematology: Remicade and Renflexis require indication-specific initiation criteria, MTX/NSAID or biologic history where applicable, and positive clinical response for continuation. Retevmo requires RET fusion/rearrangement and disease-status or prior-systemic-treatment documentation. Rozlytrek requires ROS1- or NTRK-positive disease without an acquired resistance mutation. Rubraca requires BRCA/PALB2 or other disease-specific criteria, prior therapy, and GnRH therapy/orchiectomy when required. Santyl requires wound documentation initially and evaluation showing inadequate granulation for continuation. Sapropterin requires PKU diagnosis, pretreatment phenylalanine above 6 mg/dL for an initial trial, and documented biochemical or clinical improvement for continuation. Scemblix requires CML diagnosis, BCR-ABL/Philadelphia chromosome or mutation documentation, and prior TKI history. Sorafenib requires oncology criteria and, for GIST, prior treatment history. Stivarga requires advanced/metastatic colorectal disease with prior treatment and Lonsurf failure/intolerance/contraindication, or prior treatment for appendiceal disease. Sunitinib requires disease-specific RCC or oncology documentation. Sympazan requires seizure indication and age criteria; Synarel requires CPP testing, bone age, onset age, and age limits. Tabrecta and Tepmetko require MET exon-14 skipping mutation and recurrent/advanced/metastatic NSCLC. Tafinlar requires BRAF V600 mutation, disease status, and trametinib or other required combination; document oncology information. Talzenna requires recurrent/locally advanced/metastatic or unresponsive breast cancer with germline BRCA mutation. Tasigna/nilotinib requires CML/ALL/GIST/melanoma disease, BCR-ABL or mutation results, and prior-TKI history. Tasimelteon requires blindness/no light perception or confirmed Smith-Magenis syndrome, age, specialist, and continuation response. Tavneos requires serologically confirmed MPO/PR3 ANCA-associated vasculitis, standard combination therapy, and continuation benefit. Tecentriq requires oncology indication, disease stage, biomarker, combination, and treatment-line documentation. Testosterone products require two low morning testosterone levels initially, a qualifying pre-treatment level for continuation, and documentation for gender dysphoria; age-related hypogonadism alone is insufficient. Thalidomide requires chronic GVHD unresponsive to other therapies. Tibsovo/ivosidenib requires susceptible IDH1 mutation and disease-specific AML, cholangiocarcinoma, or CNS criteria. Tobramycin requires Pseudomonas culture or history. Tofacitinib requires prior TNF-inhibitor failure/intolerance/contraindication and continuation benefit. Treprostinil requires right-heart catheterization, mean pulmonary artery pressure above 20 mmHg, wedge pressure 15 mmHg or less, and PVR above 2 Wood units for new starts. Trikafta requires CF eligibility, age, specialist, and no incompatible CFTR potentiator. Trintellix requires failure/intolerance/contraindication to an SSRI, SNRI, mirtazapine, or bupropion. Trulicity requires the applicable diabetes indication and age 10 or older. TruQap requires HR-positive, HER2-negative, PIK3CA/AKT1/PTEN-related breast-cancer criteria and combination therapy. Truxima/rituximab requires RA initiation criteria, CD20-positive malignancy where applicable, and continuation documentation. Tucatinib requires HER2-positive oncology disease, RAS/BRAF status where applicable, trastuzumab combination, and prior-treatment rules. Turalio requires CSF1R mutation and symptomatic or relapsed/refractory disease where applicable. Tyenne requires RA or interstitial-lung-disease criteria and continuation benefit. Ubrelvy requires failure/intolerance/contraindication to at least one triptan. Uceris requires failure/intolerance/contraindication to a 5-ASA. Venclexta requires disease, mutation, treatment-line, and combination criteria. Veppanu requires HR-positive, HER2-negative, ESR1-mutated advanced/recurrent breast cancer after endocrine therapy. Verzenio requires HR-positive/HER2-negative breast cancer and endocrine combination or single-agent criteria. Vigabatrin requires failure of at least two antiepileptic drugs for focal seizures and age criteria. Vonjo requires myelofibrosis risk, platelet count or high-risk symptom criteria. Voranigo requires IDH1/IDH2-mutated oligodendroglioma, astrocytoma, or high-grade glioma and surgery/residual/recurrent/progressive status. Voriconazole requires oral or IV route. Vosevi requires HCV RNA, genotype, prior treatment, hepatic status, and AASLD-IDSA review. Vyndamax requires ATTR-CM symptoms, cardiac imaging/scintigraphy, TTR confirmation, exclusion of light-chain amyloidosis, and continuation response. Vyvgart continuation requires no unacceptable toxicity and positive response. Xifaxan requires recurrence history and limits on initial and repeat 14-day courses; recurrent C. difficile products require positive stool testing and timing after antibiotics. Xospata requires FLT3-mutated AML or qualifying FLT3 neoplasm and treatment-line documentation. Xpovio requires prior therapy for multiple myeloma or at least two systemic lines for B-cell lymphoma. Zarxio requires chemotherapy timing of at least 24 hours and qualifying neutropenia/FN criteria. Zejula requires ovarian, uterine leiomyosarcoma, or BRCA-mutated prostate-cancer criteria. Zelboraf requires BRAF mutation and disease-specific status, including required cobimetinib combination where applicable. Zirabev requires oncology/ophthalmic indication documentation and Part A/B routing. Zolinza requires listed lymphoma indication. Zonisade requires focal-seizure criteria, generic anticonvulsant and Xcopri steps when applicable, and age 16 or older. Ztalmy requires age 2 or older. Zurzuvae requires postpartum-depression diagnosis confirmed by a standardized rating scale. Zymfentra requires continuation response for ulcerative colitis or Crohn disease. Zyprexa Relprevv requires established tolerability with oral olanzapine.
    • Other required steps: Document bisphosphonate failure or clinical reason to avoid IV bisphosphonate for hypercalcemia therapies; prior lecanemab infusion for Leqembi Iqlik; prior megestrol suspension for megestrol tablets; required BRAF, EGFR, RET, ROS1, KRAS, MET, HER2, BRCA, ESR1, IDH, FLT3, CSF1R, KIT, FGFR, ALK, NTRK, and TTR testing when applicable; and treatment-resistant schizophrenia, depression, anxiety, insomnia, rhinitis, alcohol-withdrawal, anticholinergic, and CNS-polypharmacy alternatives where required.
    • Denial risks: Indication or criteria not established; missing molecular, diagnostic, specialist, objective, or prior-treatment documentation; no documented continuation response; acquired resistance mutation where exclusion applies; duplicate CFTR potentiator use; ketoconazole contraindications or hepatic impairment; COVID-19 use of ivermectin; potent CYP3A4 inhibitor use with dasatinib or ergotamine; temazepam or terbinafine age/duration limits; annual terbinafine duration exceeded; toremifene QT prolongation, hypokalemia, or hypomagnesemia; pimecrolimus use outside restricted criteria; Orkambi combination or prescriber restriction; and failure to establish icatibant/HAE eligibility.
    Billing Rule

    Benefit Determination, Billing, and Submission Controls

    Before submitting a Part D request, determine whether the medication is payable under Medicare Part A or Part B and document the site of care and dispensing or administration setting. Part A or Part B responsibility takes precedence; Part D PA should not be used when coverage is available under another Medicare benefit.

    • Part B versus Part D: For drugs listed as potentially covered under Part B or Part D, submit the use, route, site of care, and whether the drug is administered or dispensed so the benefit can be determined. This applies to the broad Part B/D group and products such as trastuzumab products, lidocaine products, Pulmozyme, tobramycin, treprostinil, Zirabev, and other provider-administered therapies.
    • Part A or Part B precedence: Part D coverage is denied when coverage is available under Part A or Part B as the medication is prescribed, dispensed, or administered. Route requests to the responsible benefit and document the coverage determination; pending CMS review groups remain subject to CMS review and should not be treated as established Part D criteria.
    • Biosimilar substitution: Kanjinti, Ogivri, Ontruzant, Herceptin/Herceptin Hylecta, Trazimera, and related trastuzumab products require the applicable substitution rule, including an intolerable adverse event to Trazimera not attributable to the active ingredient where specified. Oncology indication, HER2/RAS/BRAF status, combination partner, prior HER2 treatment, and maintenance rules must still be documented.
    • High-risk medication controls: Confirm age, cumulative duration, annual limits, prerequisite alternatives, benefit-risk attestation, anticholinergic burden, CNS polypharmacy, and monitoring plan. Missing documentation can result in denial even when the drug has an otherwise covered indication.
    • Required submission package: Include diagnosis and objective measurements; laboratory, pathology, imaging, genetic, molecular, or biopsy confirmation; specialist attestation when required; prior treatment names, dates, outcomes, intolerance or contraindication; requested dose, route, duration, and site of care; and continuation response or absence of toxicity. Document failure of prerequisite therapy and any reason a required alternative cannot be used.
    • Common exclusions and routing risks: Do not submit for excluded COVID-19 use, duplicate CFTR potentiator therapy, contraindicated ketoconazole combinations, hepatic impairment exclusions, acquired-resistance exclusions, unestablished indication or eligibility, or requests lacking required Part A/Part B determination. Annual or cumulative duration limits apply to high-risk drugs, oral terbinafine, zolpidem, hydroxyzine/guanfacine/meclizine/promethazine, temazepam, and other products identified in the criteria.
    Testosterone confirmationInitial hypogonadism therapy requires at least two confirmed low morning serum total testosterone concentrations; continuation requires one confirmed low morning concentration documented before therapy began.
    Pulmonary arterial hypertension hemodynamicsFor new treprostinil starts, right-heart catheterization must confirm pulmonary arterial hypertension with mean pulmonary arterial pressure greater than 20 mmHg, pulmonary capillary wedge pressure no greater than 15 mmHg, and pulmonary vascular resistance greater than 2 Wood units.
    Quantity limits and coverage durations
    ClomipramineCoverage duration is 1 month for short-term anxiety relief, 4 months for anxiety disorders, and the plan year for other diagnoses.
    CresembaCoverage duration is 3 months for invasive aspergillosis, 6 months for invasive mucormycosis, and 1 month for esophageal candidiasis or fungal peritoneal-dialysis-associated peritonitis.
    Clorazepate and selected high-risk medicationsClorazepate requires authorization beyond 5 cumulative days per year. Selected high-risk medications, including guanfacine ER, meclizine, promethazine, and cyclobenzaprine, require authorization beyond 30 cumulative days per year.
    Droxidopa and zolpidemDroxidopa coverage is 3 months. Zolpidem requires authorization beyond 90 cumulative days per year.
    Posaconazole and PrevymisPosaconazole DR coverage is 3 months for treatment and 6 months for prophylaxis. Prevymis coverage is 7 months.
    Quinine sulfate, Santyl, sapropterin, and SYNARELQuinine sulfate coverage is 1 month; Santyl coverage is 3 months; sapropterin coverage is 2 months for the initial trial and the plan year for continuation; SYNAREL coverage for endometriosis is limited to 6 months total.
    Terbinafine, Uceris, voriconazole, Vowst, and XifaxanTerbinafine standard coverage is 12 weeks, with authorization above 90 cumulative days per year; Uceris is 2 months; voriconazole is 6 months; Vowst is 1 month; Xifaxan is 14 days for IBS-D or SIBO and 6 months for reducing overt hepatic encephalopathy recurrence.
    Neurogenic orthostatic hypotension is orthostatic hypotension associated with primary autonomic failure, dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy.
    PEComaA tumor type that includes perivascular epithelioid cell tumors and related angiomyolipoma or lymphangioleiomyomatosis subtypes.